Viva Biotech Holdings (HK:1873) has released an update.
Viva Biotech Holdings has successfully adopted its Viva Shanghai Phase I and Phase II Share Option Schemes, with shareholders’ approval leading to the immediate effectivity of both schemes. The company has updated its share option grants, now extending 7,320,000 Phase I and Phase II share options to 11 and 21 incentive participants respectively, with slight adjustments due to personnel changes. These grants are set to be formalized and implemented for the incentive participants on June 14, 2024.
For further insights into HK:1873 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
